2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Capsule Summary Slidesets

Updated data on roxadustat in patients with lower-risk MDS from the open-label portion of an ongoing randomized, double-blind phase III study suggest that roxadustat reduces transfusion burden and enables transfusion independence.

Released: December 14, 2020

In this phase II study in patients with myelofibrosis-associated anemia and RBC transfusion dependence, luspatercept meaningfully improved transfusion independence with durable responses.

Released: December 18, 2020

Durable hematocrit and molecular responses with long-term ropeginterferon α-2b therapy for patients with polycythemia vera.

Released: December 11, 2020

Imetelstat, a telomerase inhibitor, shows dose-dependent improvements in OS and trends in correlation with other clinical benefits in patients with JAK inhibitor–refractory, high-risk myelofibrosis.

Released: December 10, 2020

Combination therapy with CPI-0610, a novel BET inhibitor, plus ruxolitinib shows promising activity in JAK inhibitor–naive patients with myelofibrosis in this phase II study.

Released: December 9, 2020

Addition of pevonedistat to azacitidine significantly prolonged EFS, with a trend for extended OS and evidence of activity among patients with poor prognostic markers (eg, TP53).

Released: December 14, 2020

In this phase III study in patients with newly diagnosed advanced myeloproliferative CMML comparing decitabine vs hydroxyurea no differences in EFS, OS, or transformation to AML were reported.

Released: December 14, 2020

Results of this open-label phase II study show that undergoing HSCT leads to improved outcomes in older patients with high-risk MDS when compared with no HSCT.

Released: December 10, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue